The clinic explains the investigational drug acts on GLP-1, GIP and glucagon receptors, which play roles in appetite, blood sugar and energy use.
Recap by typeshit. Post by @perlmanmedicalwellness on Instagram.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
A law firm backed explainer that notes 4,025 cases pending in MDL 3094 as of October 2026, with no trials or settlements yet, alongside a case review pitch.
Ashlee Amborn says she conceived one month into GLP-1 use for PMOS. A review hints at a fertility link, but doctors say to stop the drug about two months before trying.
Loading…